$6.89
0.121.77%
At close: Aug 14, 5:00 PM EST
Aligos Therapeutics Inc Earnings Estimates
ALGSNASDAQ
Aligos Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:ALGS
Aligos Therapeutics (ALGS) is scheduled to report Q3 earnings on November 5, 2026. Analysts estimate EPS of $-2.58 and quarterly revenue of $5.37M.
In the most recent quarter (Q2), Aligos Therapeutics reported EPS of $-0.14, beating estimates of $-1.28 by 0.89%. Revenue came in at $0, missing the estimate of $18.88M by 1%.
Aligos Therapeutics has beaten EPS estimates in 3 consecutive quarters.
Over the last 4 quarters, Aligos Therapeutics has averaged an EPS surprise of 0.4% and a revenue surprise of 2.33%.
Earnings Date
Nov 5
EPS Estimate
$-2.580
Quarterly Revenue Estimate
$5.37M
Annual Revenue
$31.52M
as of Jun 30
Aligos Therapeutics Earnings History
Analyze the earnings history of Aligos Therapeutics using advanced sorting and filters.
Aligos Therapeutics (ALGS) Earnings Per Share
The chart below shows Aligos Therapeutics's reported EPS compared to analyst estimates over recent quarters.
Aligos Therapeutics (ALGS) Revenue
The chart below shows Aligos Therapeutics's reported revenue compared to analyst estimates over recent quarters.
FAQ
When is Aligos Therapeutics (NASDAQ:ALGS) reporting earnings?
Aligos Therapeutics (ALGS) is scheduled to report earnings on November 5, 2026. The last reported earnings were for reported on August 6, 2026 for Q2.
What were the latest earnings per share (EPS) for Aligos Therapeutics (NASDAQ:ALGS)?
The Actual EPS was $-0.14, which beat the estimate of $-1.28.
What were Aligos Therapeutics’s (NASDAQ:ALGS) revenues?
The Actual Revenue was $0, which missed the estimate of $18.88M.
